These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
272 related articles for article (PubMed ID: 30588904)
81. Pimavanserin: An Inverse Agonist Antipsychotic Drug. Howland RH J Psychosoc Nurs Ment Health Serv; 2016 Jun; 54(6):21-4. PubMed ID: 27245248 [TBL] [Abstract][Full Text] [Related]
82. Evidence for using pimavanserin for the treatment of Parkinson's disease psychosis. Tampi RR; Tampi DJ; Young JJ; Balachandran S; Hoq RA; Manikkara G World J Psychiatry; 2019 Jun; 9(3):47-54. PubMed ID: 31211112 [TBL] [Abstract][Full Text] [Related]
83. Treatment of Psychosis in Parkinson's disease and sudden death. Kyle K; Bronstein JM Parkinsonism Relat Disord; 2020 Oct; 79():127. PubMed ID: 32943345 [No Abstract] [Full Text] [Related]
84. Pimavanserin (Nuplazid) for Parkinson's disease psychosis. Med Lett Drugs Ther; 2016 Jun; 58(1496):74-5. PubMed ID: 27249096 [No Abstract] [Full Text] [Related]
85. Dementia-related psychosis and the potential role for pimavanserin. Cummings JL; Devanand DP; Stahl SM CNS Spectr; 2022 Feb; 27(1):7-15. PubMed ID: 32811586 [TBL] [Abstract][Full Text] [Related]
86. Falls and Fractures in Patients with Parkinson's Disease-Related Psychosis Treated with Pimavanserin vs Atypical Antipsychotics: A Cohort Study. Layton JB; Forns J; Turner ME; Dempsey C; Bartsch JL; Anthony MS; Danysh HE; Ritchey ME; Demos G Drugs Real World Outcomes; 2022 Mar; 9(1):9-22. PubMed ID: 34718963 [TBL] [Abstract][Full Text] [Related]
87. Treatment of psychosis in Parkinson's disease: safety considerations. Fernandez HH; Trieschmann ME; Friedman JH Drug Saf; 2003; 26(9):643-59. PubMed ID: 12814332 [TBL] [Abstract][Full Text] [Related]
88. New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer's disease: focus on brexpiprazole and pimavanserin. Caraci F; Santagati M; Caruso G; Cannavò D; Leggio GM; Salomone S; Drago F F1000Res; 2020; 9():. PubMed ID: 32695312 [TBL] [Abstract][Full Text] [Related]
89. Assessing the risks of treatment in Parkinson disease psychosis: An in-depth analysis. Longardner K; Wright BA; Alakkas A; You H; Xu R; Liu L; Nahab FB PLoS One; 2023; 18(1):e0278262. PubMed ID: 36706079 [TBL] [Abstract][Full Text] [Related]
90. Evaluating pimavanserin tartrate as a treatment in Parkinson's disease. Müller T Expert Opin Pharmacother; 2024 Oct; ():. PubMed ID: 39403823 [TBL] [Abstract][Full Text] [Related]
91. Pimavanserin in the Treatment of Parkinson's Disease Psychosis: Meta-analysis and Meta-regression of Randomized Clinical Trials. Mansuri Z; Reddy A; Vadukapuram R; Trivedi C; Amara A Innov Clin Neurosci; 2022; 19(1-3):46-51. PubMed ID: 35382074 [TBL] [Abstract][Full Text] [Related]
92. Can pimavanserin help patients with Parkinson disease psychosis? de la Cruz J; Canal C JAAPA; 2019 Jan; 32(1):44-45. PubMed ID: 30589736 [TBL] [Abstract][Full Text] [Related]
93. Update on the treatment of Parkinson's disease psychosis: role of pimavanserin. Combs BL; Cox AG Neuropsychiatr Dis Treat; 2017; 13():737-744. PubMed ID: 28331324 [TBL] [Abstract][Full Text] [Related]